← VYNE
VYNE— VYNE Therapeutics Inc.
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Total Revenues | $477.0M-48.8% | $931.0M+17.7% | $791.0M | $0-100.0% | $62.0M |
| Research and development | $18.39B-5.9% | $19.54B-55.1% | $43.53B-15.0% | $51.20B-20.6% | $64.47B |
| Selling, general and administrative | $16.39B-19.3% | $20.30B-77.3% | $89.54B+98.5% | $45.11B+221.9% | $14.01B |
| Total Operating Expenses | $34.77B-12.7% | $39.84B-85.4% | $272.15B+182.6% | $96.32B+22.7% | $78.49B |
| Operating Loss | -$34.30B+11.9% | -$38.91B-115.4% | $252.55B+163.4% | $95.87B+28.0% | $74.89B |
| Interest expense | $0+100.0% | -$5.61B-227.8% | $4.39B+376.7% | $921.0M | $0 |
| Other income (expense), net | $363.0M+368.9% | -$135.0M+87.8% | -$1.11B+22.9% | -$1.44B-53.0% | -$941.0M |
| Loss from continuing operations before income taxes | -$33.93B+24.0% | -$44.66B-117.5% | $255.83B+168.3% | $95.35B+28.9% | $73.95B |
| Income tax expense (benefit) | $13.0M+102.9% | -$448.0M-73.6% | -$258.0M-46.6% | -$176.0M-183.0% | $212.0M |
| Loss from continuing operations | -$33.95B+23.2% | -$44.21B | — | — | — |
| Income (loss) from discontinued operations, net of income taxes | $10.73B+136.9% | -$29.12B | — | — | — |
| Net Loss | -$23.21B+68.3% | -$73.33B-128.7% | $255.57B+168.5% | $95.18B+28.3% | $74.16B |
| Loss per share from continuing operations, basic (in dollars per share) | -$11K+31.1% | -$15K | — | — | — |
| Loss per share from continuing operations, diluted (in dollars per share) | -$11K+31.1% | -$15K | — | — | — |
| (Loss) income per share from discontinuing operations, basic (in dollars per share) | $3K+133.1% | -$10K | — | — | — |
| (loss) income per share from discontinuing operations, diluted (in dollars per share) | $3K+133.1% | -$10K | — | — | — |
| Loss per share basic (in dollars per share) | -$7K+71.6% | -$26K-425.4% | $8K | — | — |
| Loss per share diluted (in dollars per share) | -$7K+71.6% | -$26K-425.4% | $8K | — | — |
| Weighted average shares outstanding - basic (in shares) | $3.2M+11.4% | $2.9M-91.2% | $32.4M | — | — |
| Weighted average shares outstanding - diluted (in shares) | $3.2M+11.4% | $2.9M-91.2% | $32.4M | — | — |
| Royalty revenues | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.